Related Experiment Videos
Molecular basis for stem cell transplantation in indolent lymphomas
1Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
The Cancer Journal From Scientific American
|July 22, 1998
Summary
High-dose stem cell transplantation (SCT) offers a path to cure indolent lymphomas by eradicating minimal residual disease (MRD). Achieving molecular complete remission through SCT significantly improves disease-free survival in these patients.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Indolent lymphomas are often infiltrated by cancer cells in the bone marrow.
- Patients frequently develop chemotherapy resistance and reduced marrow reserve after extensive prior treatment.
- Unique genetic markers in indolent lymphomas allow for sensitive detection of minimal residual disease (MRD).
Purpose of the Study:
- To evaluate the effectiveness and safety of stem cell transplantation (SCT) for treating indolent lymphomas.
- To determine if SCT can eradicate detectable cancer cells after treatment.
- To assess the impact of MRD eradication on patient outcomes.
Main Methods:
- Review of studies involving autologous and allogeneic SCT in indolent lymphoma patients.
- Utilizing polymerase chain reaction (PCR) to detect and quantify MRD.
- Correlation of MRD status post-SCT with disease-free survival.
Main Results:
- SCT is a safe procedure for patients with indolent lymphomas.
- High-dose therapy and SCT can eradicate PCR-detectable MRD in a substantial number of patients.
- Eradication of MRD is strongly linked to significantly prolonged disease-free survival.
Conclusions:
- Stem cell transplantation can achieve molecular remission in indolent lymphomas.
- Attaining molecular complete remission should be the therapeutic goal for curative intent.
- SCT represents a promising strategy for improving long-term outcomes in indolent lymphoma.